Joseph K Belanoff Exercises Options at Corcept Therapeutics Inc (CORT) — SEC Form 4, Jan 26, 2021

SEC Form 4 · No Market Transaction

Option Exercise

Derivative exercise — no open market transaction.

Reporting Owner

Joseph K Belanoff

CEO

TXN 2021-01-22 · FILED 2021-01-26

Equity Position 3.3M sh 2,980,302 → 3,299,214

Equity Change +10.7% shares held after vs before

Filing Lag 2 business days within 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

Corcept Therapeutics Inc

CORT CIK 0001088856

Reporting Owner

Name	Relationship
Joseph K Belanoff CIK 0001286199	Director CEO

Joseph K Belanoff at Corcept Therapeutics Inc Full insider history

Bought (12 mo) —

Sold (12 mo) $10,384,853

More from this insider at Corcept Therapeutics Inc

Non-Derivative Securities Transactions

Title	Date	Type	Shares	Price	Net Total	Post-Txn	Ownership
Common Stock	2021-01-22	M - Exercise	800,000 A	$4.42	+$3,536,000	3,299,214	Direct
Common StockF1	2021-01-22	F - Tax Payment	481,088 D	$28.06	-$13,499,329	2,818,126	Direct

Derivative Securities Transactions

Title	Strike	Date	Type	Shares	Price	Expiration	Underlying	Ownership
Stock Option (Right to Buy)F2	$4.42	2021-01-22	M - Exercise	800,000 D	$0.00	2021-05-19	800,000 Common Stock	Direct

Footnotes (2)

F1: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of stock options that occurred on January 22, 2021. The options subject to the net exercise were to expire on May 19, 2021. Show more
F2: Fully exercisable. Show more

Institutional Holders

Largest by reported value

5%+ Holders · 13D/G 3 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at Corcept Therapeutics Inc

GET /v1/forms/4/0000899243-21-003420 API docs